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Abstract
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance
phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array
(TLDA) was used to characterise the expression of 380 genes associated with chemotherapy resistance in IGROVCDDP cells.
Paclitaxel resistance in IGROVCDDP is mediated by gene and protein overexpression of P-glycoprotein and the protein is
functionally active. Cisplatin resistance was not reversed by elacridar, confirming that cisplatin is not a P-glycoprotein
substrate. Cisplatin resistance in IGROVCDDP is multifactorial and is mediated in part by the glutathione pathway and
decreased accumulation of drug. Total cellular glutathione was not increased. However, the enzyme activity of GSR and
GGT1 were up-regulated. The cellular localisation of copper transporter CTR1 changed from membrane associated in IGROV-
1 to cytoplasmic in IGROVCDDP. This may mediate the previously reported accumulation defect. There was decreased
expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum
accumulation defects in platinum-resistant cell lines. Cellular localisation of MRP1 was also altered in IGROVCDDP shifting
basolaterally, compared to IGROV-1. BRCA1 was also up-regulated at the gene and protein level. The overexpression of P-
glycoprotein in a resistant model developed with cisplatin is unusual. This demonstrates that P-glycoprotein can be up-
regulated as a generalised stress response rather than as a specific response to a substrate. Mechanisms characterised in
IGROVCDDP cells may be applicable to relapsed ovarian cancer patients treated with frontline platinum/taxane
chemotherapy.
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Introduction
The prognosis for women with ovarian cancer is very poor. The
majority of patients present with advanced disease and the long-
term survival in these patients is 10–30% [1]. Current treatment of
ovarian cancer is surgery followed by platinum/taxane combina-
tion chemotherapy [1]. The chemotherapeutic drugs cisplatin and
paclitaxel are used in the treatment of many solid tumours,
including ovarian carcinoma. Cisplatin binds to the DNA strand,
hindering both DNA replication and RNA translation and
eventually triggering apoptosis. Paclitaxel causes cytotoxicity by
binding to and stabilising polymerised microtubules. Due to their
differing mechanisms of action, platinums and taxanes are often
combined in cancer therapy. Initial responsiveness to chemother-
apy in ovarian cancer is high, but up to 80% of patients will
eventually relapse and become platinum/taxane resistant.
The IGROVCDDP cisplatin-resistant ovarian cell line is an
unusual cisplatin-resistant model, as it is also cross-resistant to
paclitaxel. When acquired cisplatin resistance is produced in cell
lines, only 17% are also resistant to paclitaxel [2]. 41% of cisplatin
drug-resistant models are not resistant to paclitaxel and 28% of
cell models become hypersensitive to paclitaxel [2]. This suggests
that the majority of cancer patients would benefit from receiving
chemotherapy which alternates between cisplatin and paclitaxel,
as developing resistance to one drug is less likely to result in
resistance to the other. The challenge is how to identify which
patients will respond well to alternating therapy between cisplatin
and paclitaxel. This is because while the majority of cancer
patients may respond well to this treatment strategy, the cross
resistant cohort, would respond poorly and need to be treated with
alternate therapy.
IGROVCDDP models the resistance phenotype of ovarian
cancer patients who have failed standard frontline combination
platinum/taxane chemotherapy. Chemotherapeutic drugs which
IGROVCDDP is sensitive to may be suitable for the treatment of
platinum/taxane resistant ovarian cancer. Studying the
IGROVCDDP drug-resistant model will allow us to understand
the mechanisms of cross resistance between platinums and
taxanes. It is our aim to translate molecular markers of this cross
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resistance phenotypes to the clinical treatment of relapsed drug-
resistant ovarian carcinoma.
Methods
Cell Culture and Cytotoxicity Assays
The human IGROV-1 ovarian cancer cell line and its cisplatin-
resistant variant IGROVCDDP were obtained from Prof. Jan
Schellens [3,4]. Cells were grown in antibiotic and chemotherapy-
free RPMI (Sigma #R8758) with 10% FCS (Lonza, Belgium).
Cells were maintained in a humidified atmosphere with 5% CO2
at 37uC, and were mycoplasma-free. To determine cytotoxicity cells
(16104 cells/well) were plated into flat-bottomed, 96-well plates
and allowed to attach overnight. Wells were treated in triplicate
with serial dilutions of drug in a final volume of 200 mL. Drug-free
controls were included in each assay. Plates were incubated for a
further 5 days and cell viability was determined using an acid
phosphatase assay [5].
TaqMan Low Density Array (TLDA)
Cells (1.256106 cells/10 cm dish) were plated and allowed to
attach and grow for 3 days to reach 70–80% confluence. The cells
were then trypsinised, washed in 10 mL PBS, centrifuged and the
supernatant removed. The cell pellets were stored at 280uC prior
to analysis. Total RNA was prepared using a RNeasy Mini Kit
(Qiagen, UK). The TLDA array was performed on biological
triplicate samples as described in Gillet et al. 2011 [6]. The median
expression of each sample was subtracted from all gene expressions
for that sample. The data was analysed using BRB ArrayTools, a
microarray-data statistical analysis tool (http://linus.nci.nih.gov/
BRB-ArrayTools.html) [7]. Genes expressed by less than 50% of
the samples were filtered out and a univariate two-sample T-test
was performed to determine genes that were significantly different
between IGROV-1 and IGROVCDDP based on a p,0.01 cutoff.
Epirubicin Accumulation Assay
Cells were plated at a density of 2.56105 in a non-vented T25
flask. The next day the media was removed and the cells were
treated with 1 mM epirubicin for 2 hours in the presence or
absence of 0.25 mM elacridar, 0.67 mM, 3.33 mM or 33.3 mM
cisplatin. Cells were washed with 4 mL of cold PBS and
trypsinised. The cells were centrifuged and resuspended in 1 mL
of PBS and a cell count performed (9 mL). The remaining cells
were centrifuged, supernatant removed and the pellet stored at
220uC prior to analysis. Total epirubicin was then quantified by
LC-MS following a liquid-liquid extraction sample preparation,
according to the method of Wall et al. 2007 [8].
Total Cellular Glutathione Assay
Cells were plated at a density of 1.256106 cells in a 10 cm
diameter dish and allowed to attach overnight. The cells were drug
treated for 24 hours, then trypsinised and a cell count performed.
The cells were washed in 10 mL PBS, centrifuged and the
supernatant removed. The cell pellets were stored at 220uC prior
to analysis. Total glutathione was determined using a modification
of Suzakake et al. [9]. Cell pellets were lysed in 150 mL water and
sonicated, 12.5 mL of 30% sulfosalicyclic acid was added and the
Table 1. Antibodies for western blotting and confocal microscopy.
Protein kDa Host Supplier Catalogue #
Dilution
Western
Dilution
Confocal
ATP1A1 110 Mouse Abcam ab2872 1:250 N/A
ATP7A 180 Rabbit Gift from Prof. Anthony Monaco as described [11] 1:1000 N/A
BCRP 72 Mouse Alexis ALX-801-029-C250 1:250 N/A
BRCA1 220 Rabbit Cell Signalling Technology 9010 1:500 N/A
b-Actin 42 Mouse Sigma A5441 1:10,000 N/A
CTR1/SLC31A1 30 Rabbit Novus NB100-402 1:1000 1:250
FBP N/A Rabbit Novus NBP1-32293 N/A 1:250
GM130 N/A Mouse Transduction Labs 610823 N/A 1:500
GCLC (cGCS) 73 Mouse Abcam ab55435 1:500 N/A
GGT1 61.4 Mouse Sigma WH0002678M1-100UG 1:1000 N/A
GSR 56.2 Mouse Sigma WH0002936M1-100UG 1:1000 N/A
MRP1 190 Rat Alexis ALX-801-007-C250 1:250 1:250
MRP2 180 Mouse Alexis ALX-801-016-C250 1:250 N/A
P-glycoprotein 170 Mouse Alexis ALX-801-002-C100 1:250 N/A
Anti-Mouse HRP N/A Sheep Sigma A6782 1:1000 N/A
Anti-Rabbit HRP N/A Goat Sigma A4914 1:1000 N/A
Anti-Mouse AP N/A Rabbit Sigma A4312 1:1000 N/A
Anit-Rat Alexa488 N/A Donkey Invitrogen A21208 N/A 1:500
Anti-Rabbit Alexa488 N/A Goat Invitrogen A11008 N/A 1:500
Anti-Mouse Alexa594 N/A Goat Invitrogen A11005 N/A 1:500
AP – Alkaline Phosphatase, ATP1A1 - Na+/K+ transporting alpha 1, ATP7A - ATPase, Cu++ transporting, alpha polypeptide, BCRP - Breast Cancer Resistance Protein,
BRCA1 - Breast Cancer Susceptibility Protein 1, CTR1 - solute carrier family 31 (copper transporters), member 1, FBP – Folate Binding Protein, GM130 - Golgin A2, cGCS –
gamma Glutamyl Cysteine Synthesase, GSR - Glutathione Reductase, GGT1 - Gamma Glutamyl Transpeptidase, HRP – Horseradish Peroxidase, MRP1 - Multidrug
resistance-associated protein-1, MRP2 - Multidrug resistance-associated protein-2.
doi:10.1371/journal.pone.0040717.t001
P-Glycoprotein in a Cisplatin-Resistant Cell Line
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samples were vortexed. After 30 minutes on ice, protein-free
supernatants were collected by centrifugation (12000 g for 5
minutes at 4uC). Glutathione concentration was determined using
a reaction mixture containing 20 mL of lysate or standard, 90 mL
of triethanolamine buffer, pH 8.0 (0.2 M), 30 mL of NADPH
(4 mM) and 20 uL of DTNB (6 mM). After 2 minutes at 30uC, the
reaction was started by the addition of 0.3 units of glutathione
reductase per well. The plates were read at 405 nM (preheating to
30uC) with kinetic measurement by a plate reader synergy HT,
Bio-TekH (MASON Technology). The rate of change of the
kinetic assay was then calculated by KC4 software.
Glutathione Reductase (GSR) and Gamma Glutamyl
Transpeptidase (GGT1) Enzyme Assays
Cell culture - Cells (6.256105 cells/10 cm dish) were plated and
allowed to attach overnight. Cells were then treated with 0.67 mM
cisplatin. Drug-treated cells and their controls were trypsinised and
a cell count performed. The cells were then washed in 10 mL PBS,
centrifuged and the supernatant removed. The pellet was
resuspended in 400 mL cold enzyme assay buffer (100 mM
potassium phosphate monobasic, 100 mM EDTA; pH 7.5).
16 mL of 256 Complete Protease Inhibitor (Roche, UK) was
added, and the sample was sonicated. After centrifugation
(13000 rpm for 15 minutes at 4uC) the supernatant was collected
and frozen at 280uC prior to analysis.
GSR – GSR (Sigma) standards were made up in glutathione
reductase dilution buffer (100 mM potassium phosphate mono-
basic; 100 mM EDTA; 1 mg/mL BSA; pH 7.5) ranging from
0.3–0.0037 units/mL. 40 mL of each sample and standard were
assayed in duplicate in 96 well plates. The reaction mix was then
added 160 mL total volume (2 mM oxidised glutathione (100 mL);
3 mM DNTB (50 mL); 2 mM NADPH (10 mL)).
GGT1– This method was adapted from the method of Silber
et al. [10]. GGT1 (Patricell, UK) standards were made up in water
ranging from 1000–1.6 units/L. 30 mL of each sample and
standard was assayed in duplicate in 96 well plates. 100 mL
reaction mix was then added (60 mM gamma-glutamyl-p-
nitroalinine (10 mL); 55.5 mM glyclglycine in 133.33 mM Tris
Base pH 8.5 (90 mL)).
Analysis - The plates were read at 412 nM (preheating to 30uC)
and 405 nM (preheating to 37uC) for GSR and GGT1 respec-
tively, with kinetic measurement by a plate reader as described for
the glutathione assay.
Western Blots
Cells (1.256106 cells/10 cm dish) were plated and allowed to
attach overnight. The cells were then drug-treated with cisplatin
and grown for 3 days. Cells were resuspended in 100 mL lysis
buffer (0.01 M Tris/HCl, pH 7.4) and sonicated. 20 mg of protein
was diluted in Laemmli sample buffer, boiled for 3 minutes, cooled
on ice and loaded onto 12% Tris/glycine gels with a 4% stacking
gel. Samples and molecular weight markers were then electro-
phoresised for 90 minutes at 100 V. The gels were electrotrans-
ferred to 0.45 mm nitrocellulose membranes (Biorad) for 90
minutes at 100 V using a wet transfer system (Biorad). The
membranes were blocked with 5% non-fat skim milk (Biorad) in
PBS for 2 hours, then incubated with the primary antibody
prepared in 3% skim milk/0.1% tween/PBS (Table 1) overnight
at 4uC [11]. The membranes were washed in 0.3% tween/PBS
3610 minutes and then incubated for 1 hour with a HRP-
conjugated secondary antibody (Table 1). Membranes were
washed again and exposed to luminol reagent (Santa Cruz) or
ECL advanced western blotting reagent (GE Healthcare).
Membranes were then exposed to autoradiographic film. b-actin
blots were developed using an alkaline phosphatase antibody
(Table 1) and Sigma Fast BICP reagent. Densitometry on a
minimum of n= 3 biological replicates was performed using
Quantity One software (Biorad), using local background correc-
tion. Abundance of protein was normalised to ponceau for each
sample and then each biological series was normalised to IGROV-
1.
Confocal Microscopy
Cells (1.56105 cells/well) were plated into 8-well chamber slides
and allowed to attach overnight. All washes were with PBS and all
incubations were at room temperature unless otherwise specified.
The cells were washed twice, and fixed with 4% paraformaldehyde
(Sigma) in PBS for 30 minutes at 37uC. The cells were
permabilised with 0.5% Triton-X-100 (Sigma) for 10 minutes
Table 2. TLDA IGROV-1 vs IGROVCDDP - Genes of interest by function or pathway.
Gene Full Name/Synonyms
Mean mRNA Fold
Change SD P-value
Transporters not associated with platinum resistance
ABCB1 P-glycoprotein q 11.38 0.45 2.29E–06
ABCG2 BCRP/Breast Cancer Resistance Protein Q 22.17 0.19 2.95E–02
Transporters which can directly efflux platinum
ABCC2 MRP2 cMOAT Q 23.27 0.07 1.15E–03
Transporters that do not directly efflux platinum that are potential biomarkers of platinum accumulation defects
ATP1A1 Na+/K+ transporting alpha 1 Q 24.52 0.02 1.09E–05
ABCC1 MRP1 Q 21.43 0.02 3.15E–04
Glutathione Metabolism
GSR Glutathione Reductase q 1.40 0.12 1.24E–02
GGT1 Gamma Glutamyl Transpeptidase q 4.92 1.75 5.90E–04
DNA Repair
BRCA1 Breast Cancer Susceptibility Protein 1 q 2.17 0.25 1.31E–03
doi:10.1371/journal.pone.0040717.t002
P-Glycoprotein in a Cisplatin-Resistant Cell Line
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Figure 1. P-gp in IGROV-1 and IGROVCDDP cells. A) Western blot of P-glycoprotein, IGROV-1 (open bars) and IGROVCDDP (grey bars) with and
without treatment with 0.67 mM cisplatin for 72 hours (striped bars). Representative image shown. Graph shows quantitation of n = 6 biological
repeats normalised to b-actin. * Indicates significant difference from IGROV-1 p,0.05 student’s t-test. B) Accumulation of epirubicin determined by
LC-MS. IGROV-1 (open bars) and IGROVCDDP (shaded bars). Cells were treated with 1 mM epirubicin for 2 hours, 0.25 mM elacridar, 0.67 mM, 3.33 mM
or 33.3 mM cisplatin were investigated as modulators of epirubicin accumulation. Graph shows quantitation of n = 3 biological repeats normalised to
cell number. * Indicates a significant difference between IGROV-1 and IGROV-CDDP, # Indicates a significant difference on the addition of a
modulator (p,0.05 students t-test). C) Cytotoxicity of IGROV-1 and IGROVCDDP to P-glycoprotein and non P-glycoprotein substrates.
doi:10.1371/journal.pone.0040717.g001
P-Glycoprotein in a Cisplatin-Resistant Cell Line
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and washed twice. Cells were stained with a 50 mg/mL fluorescent
TRITC solution in PBS for 40 minutes and then washed twice.
The cells were then incubated with blocking buffer (0.02% BSA in
PBS) for 30 minutes at 37uC. The cells were then incubated with
primary antibody (Table 1) for 2 hours in a humidified
atmosphere. The cells were then washed 3 times for 5 minutes
and incubated with secondary antibody (Table 1) for 1 hour. The
cells were then washed 3 times for 5 minutes. The cells were then
coverslipped using mounting media containing DAPI (Sigma) and
stored at 4uC before microscopy. Images were captured at x63
magnification and 61 zoom. Scans were performed at 1 mm
interval depths through the fixed cells, and single or merged
images are presented either as XY single planes through the mid-
section of the cells or orthogonal view.
Statistical Analysis
All experiments were performed at minimum in triplicate. Two-
sample, two tailed student’s t-tests were used to determine
significant differences using p,0.05 as a cut off.
Results
Taxane Resistance in IGROVCDDP is Mediated by P-
glycoprotein
The IGROV-1 and IGROVCDDP cells were analysed for 380
genes associated with chemoresistance by TLDA array in order to
characterise the mechanisms of platinum and taxane resistance.
145 genes were found to be significantly different between
IGROV-1 and IGROVCDDP based on a p,0.01 cutoff. Genes
chosen for further analyses were based on the most significant by
p-value as well as those pathways previously associated with
platinum and taxane resistance (Table 2). All genes listed in table
two were validated at the protein level by western blot.
The gene expression of P-glycoprotein (P-gp) is increased in
IGROVCDDP (Table 2), and there is a corresponding increase
in protein expression (Figure 1A). A 3-day treatment with low
dose cisplatin tended to increase P-gp expression in both
IGROV-1 and IGROVCDDP but this was not significant
(Figure 1A). P-gp was also confirmed to be functionally active in
IGROVCDDP with an epirubicin accumulation assay
(Figure 1B). The IGROVCDDP cells have significantly lower
levels of P-gp substrate epirubicin after a 2-hour exposure
compared to IGROV-1. When IGROVCDDP was treated with
0.25 mM of the P-gp inhibitor elacridar, which prevents the
action of the drug pump [12] the accumulated mass of epirubicin
increased and was significantly higher than that of the parent
IGROV-1 cells. The increase above the level of IGROV-1 is an
interesting observation, and may be due to the IGROVCDDP
cells being so dependent on P-glycoprotein for drug efflux; they
suffer more accumulation of drug when it is inhibited.
IGROVCDDP cells were screened for their response to a
variety of chemotherapeutics (Figure 1C). IGROVCDDP cells
are significantly resistant to non-P-gp substrates cisplatin and
carboplatin [13]. IGROVCDDP is also significantly resistant to
P-gp substrates [14]; taxanes, paclitaxel and taxotere, the
anthracycline epirubicin and vinca alkaloid vinblastine. In
contrast, IGROVCDDP is hypersensitive to treatment with
non-P-gp substrate 5-FU [15]. IGROVCDDP is resistant to
MRP1 substrate methotrexate [14] but not resistant to BCRP
substrate SN-38 (Figure 1C) [16]. Treatment with 0.25 mM
elacridar significantly reverses the resistance of the
IGROVCDDP cells to all the P-gp substrates, but not the
resistance to cisplatin, carboplatin and methotrexate.
IGROVCDDP cells are also more sensitive to elacridar
treatment than IGROV-1 (Table 3). IGROVCDDP cells have
decreased mRNA expression of BCRP (Table 2) and it is not
detectable by western blot (data not shown). This suggests that
the reversal effects seen with elacridar treatment are specific to P-
gp and not BCRP, which elacridar also inhibits.
The impact of co- or pre-treatment with cisplatin on paclitaxel
cytotoxicity was investigated and no significant change was
observed (data not shown). Similarly, co- or pre-treatment with
paclitaxel did not reverse cisplatin resistance (data not shown).
Platinum resistance is associated with an intracellular shift of
platinum uptake transporter CTR1 not resistance mediated by
MRP2.
MRP2, a transporter which can efflux cisplatin conjugates, had
decreased gene expression in IGROVCDDP (Table 2), but was
not detectable by western blot in either cell line (data not shown).
This suggests that there is no role of the platinum efflux
transporter MRP2 in the platinum resistance of IGROVCDDP.
Copper transporters can also play a role in platinum uptake
(CTR1) and efflux (ATP7A and ATP7B) [17]. A decrease in
CTR1 expression or increase in ATP7A or ATP7B could
potentially mediate platinum resistance. The IGROVCDDP cells
are 2.26 fold resistant to CuSO4 (Figure 2A) suggesting that copper
metabolism may play some role in the mechanism of resistance.
There was no significant change in the mRNA expression CTR1,
ATP7A and ATP7B on the TLDA array (data not shown). ATP7A
protein expression tended to increase in IGROVCDDP in
response to cisplatin, but this change is not significant
(Figure 2B). However, there was a significant decrease in CTR1
expression, in response to cisplatin drug treatment in the
IGROVCDDP cells (Figure 2C). CTR1 is present in the cell
membrane in IGROV-1 and shifts intracellularly to the cytoplasm
in IGROVCDDP (Figure 2D, E). There is some association of
Table 3. Resistance profile of IGROVCDDP to cisplatin and ouabain.
Drug (Units) IGROV-1 IC50 IGROVCDDP IC50
Resistant vs
Sensitive
IGROV-1+/2
Ouabain
IGROVCDDP +/2
Ouabain
Mean ± SD Mean ± SD Fold P-value n P-value P-value
Platinums
Cisplatin (mM) 0.1460.06 2.7061.15 18.73 .0.001 15
+ Ouabain 0.01 nM 0.0760.00 1.4760.72 21.69 0.027 3 0.226 0.073
Modulator as Single Agent
Ouabain (nM) 23.8469.11 3.3860.59 0.14 0.018 3
doi:10.1371/journal.pone.0040717.t003
P-Glycoprotein in a Cisplatin-Resistant Cell Line
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Figure 2. Copper Transporters in IGROV-1 and IGROVCDDP cells. A) Cytotoxicity of IGROV-1 and IGROVCDDP to CuSO4. B) ATP7A western
blot. Open bars are IGROV-1, shaded bars are IGROVCDDP and striped bars indicate treatment with 0.67 mM cisplatin for 72 hours. Representative
image shown. Graph shows quantitation of n= 4 biological repeats normalised to b-actin. C) CTR1 western blot. Representative image shown. Graph
P-Glycoprotein in a Cisplatin-Resistant Cell Line
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CTR1 with the golgi in IGROVCDDP but the staining is
consistent throughout the cytoplasm.
Transporters as Biomarkers of the Platinum
Accumulation Defect
One of most significant differentially expressed genes in
IGROVCDDP was a decrease in expression of the Na+/K+
pump (ATP1A1) (Table 2), which has previously been associated
with platinum accumulation defects [18]. Cisplatin is not
transported by ATP1A1 and altered membrane potential may
play a role in the passive accumulation of the drug. There was a
corresponding decrease in protein expression of ATP1A1
(Figure 3A) and also a sensitivity to treatment with the ATP1A1
inhibitor ouabain [19] (Table 3). However, when 0.01 nM
ouabain was co-incubated in a cisplatin cytotoxicity assay rather
than reversing the resistance in IGROVCDDP it decreased the
IC50 of both the IGROV-1 and IGROVCDDP cells equally, the
fold resistance between the two cell lines remained constant
(Table 3). IGROVCDDP was not resistant to NaCl or KCl as
single agents and the addition of 40 mM of these salts did not
significantly alter cisplatin cytotoxicity (data not shown).
Previous research has shown decreased expression and an
intracellular shift of membrane proteins MRP1 and FBP to be
associated with a defect in platinum accumulation in cisplatin-
resistant cell lines [20]. Therefore we examined MRP1 and FBP as
potential biomarkers of a defect in platinum accumulation in
IGROVCDDP. The IGROVCDDP cells have a decrease in
mRNA expression of MRP1 (Table 2) as well as a small decrease
in MRP1 protein expression in response to cisplatin treatment
(Figure 3B). MRP1 distribution was examined by confocal
microscopy (Figure 3C,D). Staining in both IGROV-1 and
IGROVCDDP cell lines is evident in the cytoplasm and
perinuclear region with some accumulations of MRP1 apparent.
In IGROV-1 there is more MRP1 above and throughout the blue
line on the orthogonal view indicating it is in the apical and mid-
section in the cells. A majority of staining in IGROVCDDP is
below the blue line it is basolaterally located. FBP is localised
mainly adjacent to the nucleus within discrete sub-cellular vesicles;
little cytoplasmic staining is evident (Figure 3E,F). There is no
change in cellular distribution of FBP between IGROV-1 and
IGROVCDDP, but a decrease in expression of FBP in
IGROVCDDP is apparent from the confocal images.
Platinum Resistance in IGROVCDDP is Associated with an
Increase in Glutathione Recycling not Increased de novo
Synthesis
The mRNA expression of glutathione reductase (GSR) and
gamma glutamyl transpeptidase (GGT1) were both significantly
increased in IGROVCDDP (Table 2). GSR functions to recycle
oxidised glutathione within the cell [21,22] and GGT1 recycles
glutathione from outside the cell membrane [21,22]. The protein
expression of GSR and GGT1 were not increased in the
IGROVCDDP cells, GSR was significantly decreased in
IGROVCDDP and there was no change in GGT1. (Figure 4A
and 4B). However, the enzyme activity of both GSR and GGT1
were significantly increased (Figure 4C and Figure 4D); suggesting
that glutathione is being recycled more inside and from outside the
cell.
IGROVCDDP cells do not have higher levels of glutathione,
and levels are not increased with low-level cisplatin treatment
(Figure 4E). The levels of glutathione were also more variable in
the IGROVCDDP cells. Treatment with 12.5 mM butathione
sulfoximine (BSO), an inhibitor of cGCS [23] significantly
decreased cellular glutathione in both the IGROV-1 and
IGROVCDDP cells (data not shown). IGROV-1 and
IGROVCDDP also have similar protein expression of cGCS
and it is not upregulated in response to low-level cisplatin
treatment (Figure 4F). BSO treatment also significantly sensitised
both cell lines to cisplatin (Figure 4G). However, the effect was
equivalent and the cisplatin fold resistance remained constant
(18.76 fold). The IGROVCDDP cells tended to be more sensitive
to BSO treatment alone in a cytotoxicity assay, however this was
not significant (Figure 4G).
IGROVCDDP has Increased BRCA1 Expression
Increased expression of the DNA repair gene BRCA1 has been
previously associated with cisplatin resistance [24]. IGROVCDDP
cells have increased mRNA (Table 2) and protein expression of
BRCA1 (Figure 5A).
Discussion
P-gp Overexpression is Unusual in a Model of Acquired
Cisplatin Resistance
Resistance to paclitaxel in IGROVCDDP cells is mediated by
an overexpression of P-gp at the gene (Table 2) and protein level
(Figure 1A). P-gp has been shown to be functionally active by
cytotoxicity assays (Figure 1C) and epirubicin accumulation assays
(Figure 1B). In contrast to other studies [25], short-term cisplatin
treatment did not modulate P-gp protein expression, activity or
taxane cytotoxicity in IGROVCDDP cells (Figure 1A, 1B, data
not shown). It is unusual but not unprecedented to see a model of
acquired cisplatin resistance overexpress P-gp (Table 4)[26–30].
This most likely represents a generalised stress response to long-
term cisplatin treatment as cisplatin is not a P-gp substrate [13]. P-
gp can be up-regulated as part of a response to increased reactive
oxygen species (ROS) within a cell [31]. This may be why P-gp
expression was induced in IGROVCDDP as ROS are also
produced in response to cisplatin [32]. However, as the
IGROVCDDP cells are grown without cisplatin in the media,
there appears to be either another stimulus favouring the
expression of P-gp or P-gp is providing a selective advantage to
IGROVCDDP cells.
Many models of acquired drug resistance will have overexpres-
sion of an transporter which effluxes the drug that was used to
develop the model. Colchicine, a P-gp substrate [33] selected for
P-gp overexpression in KB-8-5-11 cells [34] and epirubicin, a
MRP1 substrate [35] induced MRP1 expression in CCRF-CEM/
E1000 [36]. However, methotrexate, fluorouracil, chlorambucil,
cisplatin, and hydroxyurea have all been shown to transiently
induce the expression of P-gp in K562 leukaemia cells when these
drugs are not P-gp substrates [15]. It is then up to natural selection
if the cells that transiently express P-gp have any other survival
advantage and become part of the drug-resistant cell line. In some
cisplatin-resistant models which overexpress P-gp, the P-gp has no
survival advantage as is not functionally active (SNU-601/Cis10 -
Table 4) [29]. Within cisplatin-resistant P-gp overexpressing cell
shows quantitation of n = 3 biological repeats normalised to b-actin. * Indicates significant difference from IGROV-1 p,0.05 student’s t-test. CTR1
confocal microscopy in D) IGROV-1 and E) IGROVCDDP cells. XY planes are shown for DAPI (blue), Golgi (red) and CTR1 (green), a merged image is
also shown.
doi:10.1371/journal.pone.0040717.g002
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lines there can also be heterogeneity; in SKOV3/CIS P-gp
positive and negative populations were maintained after treatment
with cisplatin, indicating that P-gp has no survival advantage for
cisplatin treatment [27]. However, P-gp can have anti-apoptotic
effects distinct from those associated with transport of cytotoxic
drugs, and some may be mediated through efflux of pro-apoptotic
glucosylceramide [37,38]. It is also possible that some xenobiotic
present in the FCS used to culture the cells could assist in
maintaining the P-gp expression in IGROVCDDP.
IGROVCDDP is the only cisplatin-resistant model developed
from IGROV-1 known to overexpress P-gp and consequently
have a platinum/taxane-resistant phenotype. Cisplatin-resistant
models IGROV-1/Pt0.5 and IGROV-1/Pt1 [39] have the inverse
platinum/taxane-resistant phenotype. Other cisplatin-resistant
IGROV-1 models have been developed (IGROV-R10, IGROV-
1/CP) but they do not appear to have been examined for
resistance to P-gp substrates or P-gp expression. However, P-gp
has not been identified as differentially expressed by genomic or
proteomic profiling [40–44].
Platinum Resistance is Multifactorial
Platinum resistance in the IGROVCDDP cells is multifactorial
and involves the glutathione pathway and decreased accumulation
of drug. This could result either from a complex regulatory
pathway which controls many different mechanisms for conferring
resistance to cisplatin, or could reflect the fact that the cells were
selected in multiple steps and could therefore have accumulated
different mechanisms at each step.
IGROVCDDP cells are low-level resistant toCuSO4 suggesting a
role of copper transport in platinum resistance (Figure 2A). The
expression of uptake transporter CTR1 is reduced in
IGROVCDDP in response to cisplatin drug treatment (Figure 2C),
which may contribute to the decrease in platinum accumulation
previously reported [3]. CTR1 also shifts from being membrane
associated in IGROV-1 to cytoplasmic staining in IGROVCDDP
(Figure 2D,E). The loss of a cisplatin uptake transporter from the cell
membrane in IGROVCDDP is likely to be the cause of decreased
cellular accumulation of platinum [3]. These results suggest that
CTR1 needs to be examined for cellular localisation by immuno-
histochemistry (IHC), rather than byRT-PCR orWestern blot to be
useful as a biomarker of decreased accumulation of cisplatin.
However, high levels of CTR1 as measured by RT-PCR and IHC
have both been shown to be prognostic of sensitivity to frontline
platinum chemotherapy in ovarian cancer [45]. It has been shown
with other biomarkers of platinum resistance such as ERCC1 that
mRNA expression can be prognostic even if mRNA expression does
not directly correlate with the functional role of the protein [46].
ERCC1 is a DNA repair protein and the measurement of gene and
protein expression does not strictly correlate with DNA repair
activity. It could be similar with CTR1, gene and protein expression
being prognostic independent of predicting protein function. By also
examining protein localisation the sensitivity and specificity of
CTR1 as a biomarker may be improved.
Our results show that while total cellular glutathione is not
increased in IGROVCDDP (Figure 4E), the way glutathione is
recycled in the cell is enhanced. Increased enzyme activity of GSR
(Figure 4C) indicates oxidised glutathione is being recycled more
efficiently to its reduced form. Increased enzyme activity of GGT1
(Figure 4D) indicates that GSH is being recovered from outside the
cell and the precursor amino acids transported to be available for
synthesis of new glutathione inside the cell.
Biomarkers of Decreased Platinum Accumulation
Platinum accumulation defects mediated by decreased expres-
sion of ATP1A1 have been shown in H4-II-E/CDDP cisplatin
resistant rat hepatoma cells [18]. The activity of ATP1A1 was
previously associated with the mechanism of decreased cisplatin
accumulation in IGROVCDDP as co-treatment with the inhibitor
ouabain at a dose of 0.5 mg/mL reversed the decrease in
accumulation [3]. Our cytotoxicity assays showed no reversal of
platinum resistance when ouabain was added as an inhibitor
(Table 3). The difference in results between studies may be the
difference between a short-term high-dose ouabain treatment for
an accumulation assay and a longer-term low-dose ouabain
treatment in a cytotoxicity assay. IGROVCDDP cells are more
sensitive to ouabain as a single agent (Table 3), consistent with the
decrease in ATP1A1 protein (Figure 3A).
A mechanism has previously been described in cisplatin-
resistant cell lines with platinum accumulation defects (KB-CP20
and 7404-CP20) in which surface expression of transporters is
reduced, and some are overexpressed within cytoplasmic vesicles
[47]. Protein expression of MRP1 is reduced in KB-CP20 and
7404-CP20 [48] and the protein is localised with the golgi rather
than the cell membrane [20]. This is similar to what is observed in
IGROVCDDP, decreased mRNA expression of MRP1 (Table 2),
and decreased expression of MRP1 protein in response to cisplatin
drug treatment (Figure 3B) and altered localisation within the cell
(Figure 3C,D). KB-CP20, 7404-CP20 and IGROVCDDP cells
are all resistant to the MRP1 substrate methotrexate due to the
drug pump no longer being present on the cell surface, despite a
decrease in protein expression [49]. Decreased expression and
cytoplasmic localisation of FBP has also been associated with
platinum accumulation defects in KB-CP20 and 7404-CP20 [49].
In IGROVCDDP the localisation of FBP does not change but the
expression is decreased (Figure 4E,F). FBP is localised intracellu-
larly in discrete vesicles near the nucleus rather than membrane
associated. The altered localisation of MRP1 and FBP in
IGROVCDDP is not extreme as what is seen in KB-CP20 and
7404-CP20 cells [20]. It is clear that to use a shift in MRP1 or FBP
localisation as a biomarker of platinum accumulation defects the
proteins must be strongly associated with the cell membrane in the
parent cell line, in IGROV-1 this is not the case. Despite this
caveat, a shift in MRP1 localisation appears to be more useful as a
biomarker of a platinum accumulation defect than gene or protein
expression. It has been shown that MRP1 gene [50] and protein
expression [51] is not predictive platinum resistance in clinical
ovarian samples, consistent with the results of this study. The
localisation of MRP1 has not yet been examined in clinical
samples.
Figure 3. Biomarkers of platinum accumulation defect in IGROV-1 and IGROVCDDP cells. Open bars are IGROV-1, shaded bars are
IGROVCDDP and striped bars indicate treatment with 0.67 mM cisplatin for 72 hours. A) ATP1A1 western blot. Representative image shown. Graph
shows quantitation of n = 4 biological repeats normalised to b-actin. B) MRP1 western blot. Representative image shown. Graph shows quantitation
of n = 3 biological repeats normalised to b-actin. * Indicates significant difference from IGROV-1 p,0.05 student’s t-test. MRP1 confocal microscopy in
C) IGROV-1 and D) IGROVCDDP cells. Orthogonal images are shown for a merged image of DAPI (blue) and MRP1 (green), arrows on the side bars
indicate the apical (IGROV-1) and basolateral location of MRP1 (IGROVCDDP). FBP confocal microscopy in E) IGROV-1 and F) IGROVCDDP cells. XY
planes are shown for DAPI (blue), actin (red) and FBP (green), a merged image is also shown.
doi:10.1371/journal.pone.0040717.g003
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Figure 4. Glutathione pathway in IGROV-1 and IGROVCDDP cells. Open bars are IGROV-1, shaded bars are IGROVCDDP and striped bars
indicate treatment with 0.67 mM cisplatin. A) Total intracellular glutathione. Graph shows n= 3 biological repeats normalised to cell number. B) cGCS
western blot. Representative image shown. Graph shows quantitation of n= 4 biological repeats normalised to b-actin. C) GSR western blot.
Representative image shown. Graph shows quantitation of n= 3 biological repeats normalised to b-actin. D) GSR enzyme assay. Graph shows n= 4
biological repeats normalised to cell number. E) GGT1 western blot. Representative image shown Graph shows quantitation of n = 3 biological
repeats normalised to b-actin. E) GGT1 enzyme assay. Graph shows n= 4 biological repeats normalised to cell number. * Indicates significant
difference from IGROV-1 p,0.05 student’s t-test. # Indicates significant difference from IGROVCDDP on the addition of cisplatin. G) Modulation of
cisplatin cytotoxicity of IGROV-1 and IGROVCDDP with BSO.
doi:10.1371/journal.pone.0040717.g004
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Potential Biomarkers of Platinum/taxane Cross Resistance
Versus Inverse Resistance
The IGROVCDDP cells have increased mRNA (Table 2) and
protein expression of BRCA1 (Figure 5A), which may contribute
to platinum resistance through increased DNA repair. This result
is particularly interesting as previously we have associated an
increase in BRCA1 with the inverse resistance phenotype;
platinum resistance and taxane sensitivity [24]. While an increase
in BRCA1 may mediate taxane sensitivity in some models [52,53]
if there is an overriding mechanism of taxane resistance (such as P-
gp) this effect is cancelled out. Therefore BRCA1 expression
cannot be used as a molecular marker for platinum/taxane
resistance status without also examining P-gp.
IGROV-1/Pt0.5 and IGROV-1/Pt1, platinum-resistant and
taxane-sensitive cells, have increased cellular GSH and decreased
GGT1 enzyme activity [39] which is the reverse pattern to that
seen in the IGROVCDDP platinum/taxane-resistant cells.
Further research is needed to determine if GGT1 activity could
be used as biomarker which could predict whether a cisplatin-
resistant cell line is resistant or sensitive to paclitaxel.
Decreased expression of FBP was also seen in IGROV1/Pt 0.5
and IGROV1/Pt 1. However, decreased FBP appeared to be an
effect if cisplatin resistance rather than a cause of it as transfection
with FBP cDNA did not cause cisplatin sensitivity [54]. The
IGROVCDDP, IGROV1/Pt0.5 and IGROV1/Pt1 cells all have
decreased expression of FBP, therefore the expression of FBP may
be a useful biomarker of platinum resistance but cannot be used to
differentiate between taxane sensitivity and resistance.
Figure 5. BRCA1 in IGROV-1 and IGROVCDDP cells. Open bars
are IGROV-1, shaded bars are IGROVCDDP and striped bars indicate
treatment with 0.67 mM cisplatin for 72 hours. A) BRCA1 western blot.
Representative image shown. Graph shows quantitation of n = 4
biological repeats normalised to b-actin. * Indicates significant
difference from IGROV-1 p,0.05 student’s t-test.
doi:10.1371/journal.pone.0040717.g005
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Potential Treatment Strategies for Platinum/taxane Cross
Resistant Ovarian Cancer
The only chemotherapy drug that IGROVCDDP was more
sensitive to than IGROV-1 was 5-FU (Table 3). This suggests that
5-FU may be a suitable treatment for platinum/taxane resistant
ovarian cancer. The changes in folate metabolism, as indicated by
decreased expression of FBP (Figure 3E,F) may mediate this
sensitivity to 5-FU. Several phase II clinical trials have examined
capecitabine, a pro-drug of 5-FU, in platinum-resistant ovarian
cancer. Platinum resistance was defined as progressive disease
during or within 6 months of platinum treatment; patients in these
studies had also received taxanes and therefore are most likely
taxane resistant. The response rate of this population to
capecitabine was poor 2.8–8.5% [55,56]. This is similar to the
response seen with single-agent oxaliplatin 7.6% [57] and is worse
than retreatment with paclitaxel 35.3% [2]. Collateral sensitivity
to 5-FU is not a universal feature of platinum/taxane resistant
ovarian cancer or one would expect better results in the
capecitabine clinical trials. The sensitivity of 5-FU in
IGROVCDDP will be further investigated to determine its
mechanism so biomarkers can be developed for use in the clinic.
Conclusions
P-gp overexpression is rare in a model of acquired cisplatin
resistance. In the IGROVCDDP cells P-gp causes taxane
resistance and overrides any potential taxane sensitivity mediated
by increased BRCA1 expression. Platinum resistance is multifac-
torial and is mediated by an increase in glutathione recycling and
decreased accumulation of drug. The IGROVCDDP cells were
sensitive to 5-FU and this class of chemotherapeutics warrants
further preclinical research to determine if they are useful for the
treatment of platinum/taxane resistant ovarian cancer.
Acknowledgments
Netherlands Cancer Institute - Prof. Jan Schellens for the IGROV-1 and
IGROVCDDP cells. Dublin City University - Dr. Robert O’Connor for
the P-gp antibody. Dr. Aoife Devery for optimising the P-gp westerns. Dr.
Alex Eustace for the MRP2 positive control and antibody. Ms. Helena
Joyce for the BCRP positive and antibody. National Cancer Institute - Drs.
Michael Dean, Ding-Wu Shen, Matthew D. Hall and Mitsunori Okabe for
compiling the list of 380 MDR-linked genes for the TLDA array.
University of Oxford – Dr. Zoe Holloway and Prof. Anthony Monaco for
the ATP7A antibody. Trinity College Dublin – Dr. Anne-Marie Byrne for
the GM130 antibody.
Author Contributions
Conceived and designed the experiments: BS SR MG. Performed the
experiments: BS MH VM SR JPG. Analyzed the data: BS MH VM SR
JPG MG. Contributed reagents/materials/analysis tools: JJO MC. Wrote
the paper: BS.
References
1. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:
1371–1382.
2. Stordal B, Pavlakis N, Davey R (2007) A systematic review of platinum and
taxane resistance from bench to clinic: an inverse relationship. Cancer
Treatment Reviews 33: 688–703.
3. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH (1998) Abrogated
energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human
ovarian cancer cell line IGROV-1. Cancer Chemotherapy & Pharmacology 41:
186–192.
4. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, et al. (1998)
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight
solid-tumor cell lines in vitro. Cancer Chemotherapy & Pharmacology 41: 307–
316.
5. Martin A, Clynes M (1993) Comparison of 5 microplate colorimetric assays for
in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11: 49–
58.
6. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, et al. (2011) Clinical
Relevance of Multidrug Resistance Gene Expression in Ovarian Serous
Carcinoma Effusions. Mol Pharmaceutics 8: 2080–2088.
7. Richard Simon, Amy Lam (2007) Analysis of Gene Expression Data Using BRB-
Array Tools. Cancer Informatics 3: 11–17.
8. Wall R, McMahon G, Crown J, Clynes M, O’Connor R (2007) Rapid and
sensitive liquid chromatography-tandem mass spectrometry for the quantitation
of epirubicin and identification of metabolites in biological samples. Talanta 72:
145–154.
9. Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of L-
PAM resistant L1210 Cells confers drug sensitivity. Biochemical Pharmacology
31: 121–124.
10. Silber PM, Gandolfi AJ, Brendel K (1986) Adaptation of a gamma-glutamyl
transpeptidase assay to microtiter plates. Analytical Biochemistry 158: 68–71.
11. Cobbold C, Ponnambalam S, Francis MJ, Monaco AP (2002) Novel membrane
traffic steps regulate the exocytosis of the Menkes disease ATPase. Human
Molecular Genetics 11: 2855–2866.
12. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In Vitro and in Vivo
Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide
Derivative. Cancer Research 53: 4595–4602.
13. Hamaguchi K, Godwin AK, Yakushiji M, O’Dwyer PJ, Ozols RF, et al. (1993)
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in
ovarian cancer cell lines. Cancer Research 53: 5225–5232.
14. Choudhuri S, Klaassen CD (2006) Structure, Function, Expression, Genomic
Organization, and Single Nucleotide Polymorphisms of Human ABCB1
(MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. International
Journal of Toxicology 25: 231–259.
15. Chaudhary PM, Roninson IB (1993) Induction of Multidrug Resistance in
Human Cells by Transient Exposure to Different Chemotherapeutic Drugs.
J Natl Cancer Inst 85: 632–639.
16. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, et al. (2004)
ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamp-
tothecin) and Homocamptothecins. Journal of Pharmacology and Experimental
Therapeutics 310: 836–842.
17. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T (2007) The roles of copper
transporters in cisplatin resistance. Cancer & Metastasis Reviews 26: 71–83.
18. Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, et al. (2006) Role of
Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.
Cancer Chemotherapy & Pharmacology 57: 84–90.
19. Takeyasu K, Tamkun MM, Renaud KJ, Fambrough DM (1988) Ouabain-
sensitive (Na+ + K+)-ATPase activity expressed in mouse L cells by transfection
with DNA encoding the alpha-subunit of an avian sodium pump. Journal of
Biological Chemistry 263: 4347–4354.
20. Liang XJ, Shen DW, Garfield S, Gottesman MM (2003) Mislocalization of
membrane proteins associated with multidrug resistance in cisplatin-resistant
cancer cell lines. Cancer Research 63: 5909–5916.
21. Townsend DM, Tew KD, Tapiero H (2003) The importance of glutathione in
human disease. Biomedicine & Pharmacotherapy 57: 145–155.
22. Rahman Q, Abidi P, Afaq F, Schiffmann D, Mossman BT, et al. (1999)
Glutathione redox system in oxidative lung injury. Critical Reviews in
Toxicology 29: 543–568.
23. Drew R, Miners JO (1984) The effects of buthionine sulphoximine (BSO) on
glutathione depletion and xenobiotic biotransformation. Biochemical Pharma-
cology 33: 2989–2994.
24. Stordal B, Davey R (2009) A systematic review of genes involved in the inverse
resistance relationship between cisplatin and paclitaxel chemotherapy. Current
Cancer Drug Targets 9: 354–365.
25. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, et al. (1997)
Suppression of P-glycoprotein expression and multidrug resistance by DNA
cross-linking agents. Clinical Cancer Research 3: 1339–1346.
26. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, et al. (1993) Distinct P-
glycoprotein expression in two subclones simultaneously selected from a human
colon carcinoma cell line by cis-diamminedichloroplatinum (II). International
Journal of Cancer 53: 478–485.
27. Yang X, Page M (1995) P-glycoprotein expression in ovarian cancer cell line
following treatment with cisplatin. Oncology Research 7: 619–624.
28. Yang H, Zou W, Li Y, Chen B, Xin X (2007) Bridge linkage role played by
CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-
resistant ovarian cancer cells. Cancer Biology & Therapy 6: 942–947.
29. Xu H, Choi SM, An CS, Min YD, Kim KC, et al. (2005) Concentration-
dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Biochemical & Biophysical Research Communications 328: 618–622.
30. Parekh H, Simpkins H (1996) Cross-resistance and collateral sensitivity to
natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and
human ovarian carcinoma cells. Cancer Chemotherapy & Pharmacology 37:
457–462.
P-Glycoprotein in a Cisplatin-Resistant Cell Line
PLoS ONE | www.plosone.org 12 July 2012 | Volume 7 | Issue 7 | e40717
31. Callaghan R, Crowley E, Potter S, Kerr ID (2008 March) Review/Drug
Metabolism and Transport: P-glycoprotein: So Many Ways to Turn It On.
Journal of Clinical Pharmacology: 365.
32. Berndtsson M, Ha¨gg M, Panaretakis T, Havelka AM, Shoshan MC, et al. (2007)
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is
not associated with damage to nuclear DNA. International Journal of Cancer
120: 175–180.
33. Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers.
Drug Metabolism Reviews 34: 47–54.
34. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I (1988) Stability and
covalent modification of P-glycoprotein in multidrug-resistant KB cells.
Biochemistry 27: 7607–7613.
35. O’Connor R, O’Leary M, Ballot J, Collins CD, Kinsella P, et al. (2007) A phase
I clinical and pharmacokinetic study of the multi-drug resistance protein-1
(MRP-1) inhibitor sulindac, in combination with epirubicin in patients with
advanced cancer. Cancer Chemotherapy & Pharmacology 59: 79–87.
36. Locke VL, Davey RA, Davey MW (1999) Altered drug sensitivity in response to
idarubicin treatment in K562 human leukaemia cells. British Journal of
Haematology 106: 86–91.
37. Zhang X, Wu X, Li J, Sun Y, Gao P, et al. (2011) MDR1 (multidrug resistence
1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J Surg
Oncol 104: 466–471.
38. Lee WK, Torchalski B, Kohistani N, Thevenod F (2011) ABCB1 Protects
Kidney Proximal Tubule Cells Against Cadmium-Induced Apoptosis: Roles of
Cadmium and Ceramide Transport. Toxicological Sciences 121: 343–356.
39. Perego P, Romanelli S, Carenini N, Magnani I, Leone R, et al. (1998) Ovarian
cancer cisplatin-resistant cell lines: multiple changes including collateral
sensitivity to Taxol. Annals of Oncology 9: 423–430.
40. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, et al. (1998) Acquisition of
chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell
cycle control. International Journal of Cancer 78: 454–463.
41. Sun B, Ranish JA, Utleg AG, White JT, Yan X, et al. (2007) Shotgun
glycopeptide capture approach coupled with mass spectrometry for compre-
hensive glycoproteomics. Molecular & cellular proteomics 6[1], 141–9. 2007.
42. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, et al. (2006) Proteins
associated with Cisplatin resistance in ovarian cancer cells identified by
quantitative proteomic technology and integrated with mRNA expression levels.
Molecular & cellular proteomics 5[3], 433–43. 2006.
43. Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, et al. (2010) Analysis of
chemotherapy response programs in ovarian cancers by the next-generation
sequencing technologies. Gynecologic Oncol 117[2], 159–69. 2010.
44. Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, et al. (2006)
Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian
carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics
6[19], 5183–92. 2006.
45. Lee YY, Choi CH, Do IG, Song SY, Lee W, et al. (2011) Prognostic value of the
copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma
receiving platinum-based chemotherapy. Department of Obstetrics and
Gynecology, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul 135–710, Republic of Korea. Available.
46. DeLoia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, et al. (2011)
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in
women with advanced stage ovarian cancer treated with intraperitoneal
platinum. Gynecologic Oncology.
47. Gottesman MM, Hall MD, Liang XJ (2009) Resistance to cisplatin results from
multiple mechanisms in cancer cells. In: Bonetti A, Leone R, Muggia F, Howell
SB, editors. Platinum and Other Heavy Metal Compunds in Cancer
Chemotherapy - Molecular Mechanisms and Clinical Applications. Humana
Press. 83–88.
48. Shen DW, Goldenberg S, Pastan I, Gottesman MM (2000) Decreased
accumulation of [14C]carboplatin in human cisplatin-resistant cells results from
reduced energy-dependent uptake. Journal of Cellular Physiology 183: 108–116.
49. Shen D, Pastan I, Gottesman MM (1998) Cross-resistance to methotrexate and
metals in human cisplatin-resistant cell lines results from a pleiotropic defect in
accumulation of these compounds associated with reduced plasma membrane
binding proteins. Cancer Research 58: 268–275.
50. Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, et al. (2002)
Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin
based chemoresistance marker in ovarian carcinoma: comparative analysis with
expression of MDR1, MRP1, MRP2, LRP and BCRP.
51. Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, et al. (2002)
Cellular glutathione content, in vitro chemoresponse, and the effect of BSO
modulation in samples derived from patients with advanced ovarian cancer.
Haematology Research, Pembury Hospital, Pembury, Tunbridge Wells, Kent
TN2 4QJ, United Kingdom. Available.
52. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, et al. (2003)
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937
human breast cancer cells. British Journal of Cancer 88: 1285–1291.
53. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al. (2003)
BRCA1 functions as a differential modulator of chemotherapy-induced
apoptosis. Cancer Research 63: 6221–6228.
54. Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, et al. (1997) Relationship
between folate-binding protein expression and cisplatin sensitivity in ovarian
carcinoma cell lines. Br J Cancer 76[1], 77–82. 1997.
55. Pisano C, Morabito A, Sorio R, Breda E, Lauria R, et al. (2009) A phase II study
of capecitabine in the treatment of ovarian cancer resistant or refractory to
platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Cancer Chemother Pharmacol 64[5], 1021–7. 2009.
56. Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, et al. (2004) A
phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian
cancer. Gynecologic Oncol 93[2], 417–21. 2004.
57. Stordal B, Pavlakis N, Davey R (2007) Oxaliplatin for the treatment of cisplatin-
resistant cancer: A systematic review. Cancer Treatment Reviews 33: 347–357.
P-Glycoprotein in a Cisplatin-Resistant Cell Line
PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e40717
